🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Intelligent Prevention And Control System And Strategy For The Whole Disease Cycle Of Diabetic Nephropathy

Recruitingn/aAges 18 Years - anyAllChinese PLA General Hospital
NCT06843304 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Diabetic nephropathy is one of the most severe microvascular complications of diabetes and a major cause of premature death and disability. It has become a leading cause of end-stage renal failure both in China and worldwide, consuming substantial medical resources. The establishment of a comprehensive regulatory system for the development and progression of diabetic nephropathy is a critical need for effective prevention and control. However, there is a lack of representative cohorts covering the entire disease cycle of diabetic nephropathy both domestically and internationally, creating technical bottlenecks in comprehensively describing its developmental patterns. This project aims to expand and integrate existing large-sample natural population cohorts and prospective follow-up cohorts covering the entire disease cycle of diabetes and diabetic nephropathy. It will construct a panoram

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
T2DM Inclusion Criteria: * Age ≥18 years old, gender is not limited * Diagnosed with type 2 diabetes * A history of type 2 diabetes for more than 5 years * Negative proteinuria * Creatinine is normal * Good compliance, voluntarily sign informed consent Exclusion Criteria: * Incomplete medical records * Lack of fundus microvascular examination or new imaging technology examination results data * Combined with autoimmune diseases and tumors Type 2 diabetes patients undergoing renal biopsy Inclusion Criteria: * Age ≥18 years old, gender is not limited * Diagnosed with type 2 diabetes * Kidney damage (microalbuminuria or dominant albuminuria or renal insufficiency) * Have undergone renal puncture biopsy and have complete renal pathological diagnosis data * Sign informed consent voluntarily Exclusion Criteria: * Gestational diabetes mellitus, special type diabetes mellitus * Patients with hereditary kidney disease * Combined with autoimmune diseases * Diabetic nephropathy The indicators in the comprehensive assessment model of the risk of renal progression could not be obtained * There were pregnancy plans in the study period
💊

What it tests

  • Not listed
📍

Where

1 site
Chinese PLA General Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy